Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.37 USD
0.00 (0.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.36 -0.01 (-0.73%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.37 USD
0.00 (0.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.36 -0.01 (-0.73%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Zacks News
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spero Therapeutics (SPRO) delivered earnings and revenue surprises of 5.71% and 4.05%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NovoCure (NVCR) delivered earnings and revenue surprises of 22.50% and 10.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
by Zacks Equity Research
Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of -28% and 84.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 36.11% and 11.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 633.33% and 278.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.
Penumbra (PEN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Penumbra (PEN) will likely report strong Neuro sales growth on the strength of its RED 72 (with the proprietary SENDit technology), RED 43 and BMX81.
What's in Store for Boston Scientific (BSX) in Q3 Earnings?
by Zacks Equity Research
With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.
What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?
by Zacks Equity Research
Outside the United States, Edwards Lifesciences (EW) TAVR sales growth will likely be driven by broad-based adoption of the SAPIEN platform.
Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?
by Zacks Equity Research
Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.
Insulet (PODD) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Insulet's (PODD) global new customer starts are expected to have been strong in the third quarter.
GE HealthCare (GEHC) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.
Align Technology (ALGN) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.
Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.
All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Novartis (NVS) Announces Positive Long-Term Data on Leqvio
by Zacks Equity Research
Novartis (NVS) Leqvio shows consistent efficacy and safety beyond six years in patients with ASCVD.
Bristol Myers (BMY) Gets FDA Nod for Reblozyl Label Expansion
by Zacks Equity Research
Bristol Myers' (BMY) Reblozyl is now indicated in the United States as the first-line treatment of anemia in adults with lower-risk MDS who may require transfusions.
New Strong Buy Stocks for August 29th
by Zacks Equity Research
SPRO, FBIZ, KNSL, BMI and FDUS have been added to the Zacks Rank #1 (Strong Buy) List on August 29, 2023.
Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar
by Zacks Equity Research
Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.
Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive
by Zacks Equity Research
Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.
Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment
by Zacks Equity Research
Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.
Bristol Myers' (BMY) Opdivo Gets EC Nod for Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) obtains approval in the EU for Opdivo for the adjuvant treatment of adults and adolescents with stage IIB or IIC melanoma who have undergone complete resection.
Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.